INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/014475

Box No. II Observations where certain claims were found unscarchable (Continuation of item 2 of first sheet)	
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: 1. Claims Nos.: 5, 8 because they relate to subject matter not required to be searched by this Authority, namely: The inventions as set forth in claims 5 and 8 pertain to methods for treatment of the human body by therapy. (Article 17(2)(a)(i) of the PCT, Rule 39.1(iv) of the Regulations under the PCT) 2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:	t)
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box No. II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	
 As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. 	
any additional fee. 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:	
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

PCT/JP2004/014475

Claims 1 to 4, 6 and 7

In the inventions according to these claims, a dipeptidyl-peptidase IV inhibitor is employed as the active ingredient. Although it can be judged, based on these statements, whether or not individual compounds are dipeptidyl-peptidase IV inhibitors, no clear definition is made in the description on the specific chemical structure of the dipeptidyl-peptidase IV inhibitor. Moreover, such a structure is not self-evident for a person skilled in the art. Thus, the statements fail to make the structure clear.

In the case of specifying the active ingredient depending on its function and thus involving compounds of various chemical structures in the scope thereof as in the present application, it was a common technical knowledge at the point of the application that any compound having such a function could not be considered as having a specific pharmacological effect. Therefore, it is needed to present pharmacological data obtained by a specific pharmacological test or theoretical discussion in the description at such a level as allowing general recognition that the compounds having the above function have the specific pharmacological effect. In the description of the present case, however, a test was performed merely on one compound and it was not confirmed that the same effect could be achieved generally by the compounds having the same function.

Thus, it cannot be considered that the description discloses the inventions in a manner sufficiently clear and complete for the inventions to be carried out by a person skilled in the art, and the inventions are not sufficiently supported thereby (PCT Articles 5 and 6).

Such being the case, prior art documents were examined in preparing this international search report exclusively in a rational range based on the statements in EXAMPLES.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2004/014475

A. CLASSIFIC Int.Cl ⁷	ATION OF SUBJECT MATTER A61K45/00, 31/472, A61P3/10, 5	/50//C07D217/24				
According to International Patent Classification (IPC) or to both national classification and IPC						
B. FIELDS SE	3. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) Int.Cl ⁷ A61K45/00-45/08, 31/00-31/80, A61P1/00-43/00, C07D217/00-217/24						
	earched other than minimum documentation to the extent					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) JSTPLUS(JOIS), JMEDPLUS(JOIS), MEDLINE(STN), EMBASE(STN), BIOSIS(STN), BIOTECHABS(STN), CAPLUS(STN)						
C. DOCUMEN	NTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where app	ropriate, of the relevant passages	Relevant to claim No.			
Y	Hiroshi KIYONO et al., "Sui ß Kanjusei K* Channel to Sulfony no Kino Kyokan no Kaiseki, Oyo Sayo Kijo ni yoru Keiko Tonyok Kaihatsu", Research papers of Memorial Foundation 1999, Suzu Foundation, 2001, pages 147 to FABGHANEL, G. et al., Metform Glucose and Lipid Metabolism Secondary Failure to Sulfonylo Care, 1996, 19(11), pages 118	lured Receptor bbi Atarashii byoyaku no the Suzuken uken Memorial b 149 in's Effects on in Patients with ureas. Daibetes	1-4,6,7			
× Further d	locuments are listed in the continuation of Box C.	See patent family annex.				
"A" document to be of pa "E" earlier app filing date "L" document cited to es special ree "O" document "P" document	Special categories of cited documents: (A" document defining the general state of the art which is not considered to be of particular relevance (E" earlier application or patent but published on or after the international filing date ("C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) ("O" document referring to an oral disclosure, use, exhibition or other means being obvious to a person skilled in the art		cation but cited to understand invention claimed invention cannot be idered to involve an inventive e claimed invention cannot be estep when the document is a documents, such combination and the cart			
Date of the act	ual completion of the international search	Date of mailing of the international sea 28 December, 2004	(28.12.04)			
Name and mall	ing address of the ISA egg Patent Office	Authorized officer				
Facsimile No.		Telephone No.				

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/014475

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	Kentaro YAMADA, "Keiko Yakubutsu Ryoho no Shinsenryaku 2. Keiko Ketto Tokayaku no Tsukaiwake to Heiyo", Tonyobyogaku no Shinpo, 2002, 36, pages 292 to 296	1-4, 6, 7
Y	TRISCHITTA, V. et al., Comparison of Combined Therapies in Treatment of Secondary Failure to Glyburide. Diabetes Care, 1992, 15(4), pages 539 to 542	1-4,6,7
Y	JP 2003-238566 A (Takeda Chemical Industries, Ltd.), 27 August, 2003 (27.08.03), Claims; examples; Par Nos. [0002], [0046] to [0057] & WO 02/62764 Al	1-4,6,7
Y	Yoshiro KITAHARA et al., "Tonyobyo Ippan ni Kansuru Chiryoyaku- Sokkogata Insulin Bunpitsu Sokushinzai ni yoru Seiritekina 'To no Nagare' no Jitsugen-", Saibo, 2000, 32(12), pages 480 to 483	3
L	"SU-zai ni 2ji Muko to Kangaerareru 2gata Tonyobyo Kanja ni okeru Chosokkogata Insulin Bunpitsu Sokushinzai nateglinide(Na) no Koka", The journal of the Japan Diabetic Society, 2000, 43(suppl.1), p.S-120 (Sulfonylurea 2ji Muko o Hikiokosu Seibun to Sareru Nateglinide ni yori, Sulfonylurea 2ji Muko Tonyobyo ga Chiryo Sarerukotoga Kisai Sareteiru.)	3
L	"2gata Tonyobyo Kanja no Sulfonylurea-zai 2ji Mukorei ni Taisuru Sokkogata Shokugo Ketto Tokazai (Nateglinide) no Shiyo Keiken", Nippon Taishitsugaku Zasshi, 2001, 63(1-2), page 52 (Sulfonylurea 2ji Muko o Hikiokosu Seibun to Sareru Nateglinide ni yori, Sulfonylurea 2ji Muko Tonyobyo ga Chiryo Sarerukotoga Kisai Sareteiru.)	3